SEC Filing Summary: Form 13F Information Table
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Alphabet Inc. to the U.S. Securities and Exchange Commission. The reporting period covers holdings as of September 30, 2022. This form discloses equity securities held by institutional investment managers, detailing the issuer, class of security, CUSIP, value, and voting authority.
Key Financial Metrics and Portfolio Composition
The filing does not report Alphabet Inc.'s internal revenue, profit, or cash flow. Instead, it details the value of Alphabet's external equity portfolio. Key observations include:
- Total Disclosed Holdings: The table lists 50 distinct line items representing various issuers.
- Top Holdings by Value:
- Oscar Health Inc.: Multiple entries totaling approximately $23.5 million (21.3M shares).
- Planet Labs PBC: Approximately $17.3 million (31.9M shares).
- UiPath Inc.: Multiple entries totaling approximately $17.3 million (14.1M shares).
- Verve Therapeutics Inc.: Multiple entries totaling approximately $37.1 million (11.0M shares).
- Benson Hill Inc.: Approximately $42.1 million (15.6M shares).
- Investment Discretion: The vast majority of positions are marked as "DFND" (Discretionary), indicating Alphabet Inc. has sole or shared voting authority over these investments.
Material Changes and Sector Focus
As this is a snapshot of holdings at a specific date, the filing text does not provide comparative data against the prior quarter to calculate material changes in position size or value. However, the portfolio composition reveals a distinct strategic focus:
- Biotechnology and Healthcare: A significant portion of the portfolio consists of biotech firms (e.g., 23andMe, Alector, Beam Therapeutics, Decibel Therapeutics, Lyell Immunopharma).
- Technology and Software: Notable positions in software and data companies (e.g., Snowflake, Gitlab, New Relic, UiPath, Amplitude).
- Emerging Growth Companies: Many holdings are in companies that have recently gone public or are in early growth stages.
Guidance, Risks, and Contingencies
The filing text does not contain management commentary, future guidance, or specific risk factors related to Alphabet's operations. Standard Form 13F disclaimers apply:
- The SEC has not reviewed the information for accuracy or completeness.
- Readers should not assume the information is accurate or complete.
- The filing does not disclose short positions or derivatives other than the specific "PUT/CALL" column which is empty for all listed items.
Investor Verification Checklist
- Verify the total aggregate value of Alphabet's disclosed equity portfolio by summing the "VALUE" column (x$1,000) across all 50 entries.
- Compare these holdings against Alphabet's prior quarter 13F filing to identify new positions or significant reductions.
- Confirm the "Voting Authority" status (Sole vs. Shared) for the largest positions to understand the level of control Alphabet exerts.
- Check the current market prices of the top holdings (e.g., Oscar Health, Verve Therapeutics) to assess potential unrealized gains or losses relative to the reported values.
- Note that this filing does not reflect Alphabet's core operating business (Google, Cloud, etc.) financial performance.